ArticleJournal of virology2005
Characterization of the minimal replicator of Kaposi's sarcoma-associated herpesvirus latent origin.
Article in Journal of virology, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed.
- Bypass of LANA-DNA crosslinks by Polη ensures KSHV genome maintenance and tumor growth.Cell reports · 2026Article
- LANA-dependent transcription-replication conflicts and R-loops at the terminal repeats (TR) correlate with KSHV episome maintenance.PLoS pathogens · 2025Article
- KSHV genome harbors both constitutive and lytically induced enhancers.Journal of virology · 2024Article
- Disrupting Kaposi's Sarcoma-Associated Herpesvirus (KSHV) Latent Replication with a Small Molecule Inhibitor.Journal of medicinal chemistry · 2023Article
- Whole-genome sequencing of Kaposi sarcoma-associated herpesvirus (KSHV/HHV8) reveals evidence for two African lineages.Virology · 2022Article
- Relevance of BET Family Proteins in SARS-CoV-2 Infection.Biomolecules · 2021Review
- Control of Viral Latency by Episome Maintenance Proteins.Trends in microbiology · 2020Review
- Hitchhiking of Viral Genomes on Cellular Chromosomes.Annual review of virology · 2019Review
- Towards Better Understanding of KSHV Life Cycle: from Transcription and Posttranscriptional Regulations to Pathogenesis.Virologica Sinica · 2019Review
- Article
- Plasmid Partitioning by Human Tumor Viruses.Journal of virology · 2018Review
- Murine Gammaherpesvirus 68 Expressing Kaposi Sarcoma-Associated Herpesvirus Latency-Associated Nuclear Antigen (LANA) Reveals both Functional Conservation and Divergence in LANA Homologs.Journal of virology · 2017Article
- BET-Inhibitors Disrupt Rad21-Dependent Conformational Control of KSHV Latency.PLoS pathogens · 2017Article
- Kaposi sarcoma-associated herpesvirus: immunobiology, oncogenesis, and therapy.The Journal of clinical investigation · 2016Review
- G-quadruplex-interacting compounds alter latent DNA replication and episomal persistence of KSHV.Nucleic acids research · 2016Article
- Kaposi's Sarcoma Herpesvirus Genome Persistence.Frontiers in microbiology · 2016Review
- KSHV Genome Replication and Maintenance.Frontiers in microbiology · 2016Review
- KSHV but not MHV-68 LANA induces a strong bend upon binding to terminal repeat viral DNA.Nucleic acids research · 2015Article
- The 3D structure of Kaposi sarcoma herpesvirus LANA C-terminal domain bound to DNA.Proceedings of the National Academy of Sciences of the United States of America · 2015Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
The latency-associated nuclear antigen (LANA) of Kaposi's sarcoma-associated herpesvirus (KSHV) binds to two sites within the 801-bp-long terminal repeat (TR) and is the only viral protein required for episomal maintenance. While two or more copies of TR are required for long-term maintenance, a single TR confers LANA-dependent origin activity on plasmid DNA. Deletion mapping revealed a 71-bp-long minimal replicator containing two distinctive sequence elements: LANA binding sites (LBS1/2) and an adjacent 29- to 32-bp-long GC-rich sequence which we termed the replication element. Furthermore, the transcription factor Sp1 can bind to TR outside the minimal replicator and contributes to TR's previously reported enhancer activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.